Literature DB >> 32527543

Structure-activity relationships of tubulysin analogues.

Joel R Courter1, Joseph Z Hamilton2, Nathaniel R Hendrick2, Margo Zaval2, Andrew B Waight2, Robert P Lyon2, Peter D Senter2, Scott C Jeffrey2, Patrick J Burke3.   

Abstract

The tubulysins are an emerging antibody-drug conjugate (ADC) payload that maintain potent anti-proliferative activity against cells that exhibit the multi-drug resistant (MDR) phenotype. These drugs possess a C-11 acetate known to be hydrolytically unstable in plasma, and loss of the acetate significantly attenuates cytotoxicity. Structure-activity relationship studies were undertaken to identify stable C-11 tubulysin analogues that maintain affinity for tubulin and potent cytotoxicity. After identifying several C-11 alkoxy analogues that possess comparable biological activity to tubulysin M with significantly improved plasma stability, additional analogues of both the Ile residue and N-terminal position were synthesized. These studies revealed that minor changes within the tubulin binding site of tubulysin can profoundly alter the activity of this chemotype, particularly against MDR-positive cell types.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody-drug conjugates; Microtubule-disrupting agents; Multi-drug resistant; Structure-activity relationships; Tubulin binders; Tubulysin

Mesh:

Substances:

Year:  2020        PMID: 32527543     DOI: 10.1016/j.bmcl.2020.127241

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.

Authors:  Joseph Z Hamilton; Thomas A Pires; Jamie A Mitchell; Julia H Cochran; Kim K Emmerton; Margo Zaval; Ivan J Stone; Martha E Anderson; Steven Jin; Andrew B Waight; Robert P Lyon; Peter D Senter; Scott C Jeffrey; Patrick J Burke
Journal:  ChemMedChem       Date:  2021-02-12       Impact factor: 3.540

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.